Primary diagnosis, primary therapy, and clonal cytogenetic abnormalities in 306 patients with t-MDS/t-AML
Clinical feature . | No. patients . | Abnormality 5 (%) . | Abnormality 7 (%) . | Abnormalities 5 and 7 (%) . | Balanced rearrangement (%) . | Other abnormalities (%) . | Normal (%) . |
|---|---|---|---|---|---|---|---|
| Primary diagnosis* | |||||||
| No malignancy | 18 | 1 (6) | 13 (72) | 1 (6) | 1 (6) | 1 (6) | 1 (6) |
| Hematologic malignancy | 171 | 32 (19) | 49 (29) | 47 (27) | 9 (5) | 25 (15) | 9 (5) |
| Hodgkin disease | 77 | 13 (17) | 26 (34) | 17 (22) | 4 (5) | 14 (18) | 3 (4) |
| Non-Hodgkin lymphoma | 70 | 12 (17) | 15 (21) | 26 (37) | 4 (6) | 9 (13) | 4 (6) |
| Myeloma | 23 | 7 (30) | 8 (35) | 4 (17) | 0 | 2 (9) | 2 (9) |
| Other | 1 | 0 | 0 | 0 | 1 (100) | 0 | 0 |
| Solid tumor | 117 | 29 (25) | 22 (19) | 18 (15) | 21 (18) | 13 (11) | 14 (12) |
| Breast | 32 | 6 (19) | 10 (31) | 3 (9) | 8 (25) | 3 (9) | 2 (6) |
| Ovary | 15 | 5 (33) | 1 (7) | 3 (20) | 3 (20) | 3 (20) | 0 |
| Prostate | 13 | 3 (23) | 0 | 2 (15) | 1 (8) | 4 (31) | 3 (23) |
| Lung | 9 | 1 (11) | 2 (22) | 1 (11) | 4 (44) | 1 (11) | 0 |
| Cervix | 7 | 2 (29) | 2 (29) | 1 (14) | 0 | 0 | 2 (29) |
| Other | 41 | 12 (29) | 7 (17) | 8 (20) | 5 (12) | 2 (5) | 7 (17) |
| Primary therapy† | |||||||
| CT only | 121 | 21 (17) | 38 (31) | 25 (21) | 11 (9) | 15 (12) | 11 (9) |
| RT only | 43 | 14 (33) | 6 (14) | 6 (14) | 6 (14) | 5 (12) | 6 (14) |
| CMT | 139 | 26 (19) | 40 (29) | 34 (24) | 14 (10) | 18 (13) | 7 (5) |
Clinical feature . | No. patients . | Abnormality 5 (%) . | Abnormality 7 (%) . | Abnormalities 5 and 7 (%) . | Balanced rearrangement (%) . | Other abnormalities (%) . | Normal (%) . |
|---|---|---|---|---|---|---|---|
| Primary diagnosis* | |||||||
| No malignancy | 18 | 1 (6) | 13 (72) | 1 (6) | 1 (6) | 1 (6) | 1 (6) |
| Hematologic malignancy | 171 | 32 (19) | 49 (29) | 47 (27) | 9 (5) | 25 (15) | 9 (5) |
| Hodgkin disease | 77 | 13 (17) | 26 (34) | 17 (22) | 4 (5) | 14 (18) | 3 (4) |
| Non-Hodgkin lymphoma | 70 | 12 (17) | 15 (21) | 26 (37) | 4 (6) | 9 (13) | 4 (6) |
| Myeloma | 23 | 7 (30) | 8 (35) | 4 (17) | 0 | 2 (9) | 2 (9) |
| Other | 1 | 0 | 0 | 0 | 1 (100) | 0 | 0 |
| Solid tumor | 117 | 29 (25) | 22 (19) | 18 (15) | 21 (18) | 13 (11) | 14 (12) |
| Breast | 32 | 6 (19) | 10 (31) | 3 (9) | 8 (25) | 3 (9) | 2 (6) |
| Ovary | 15 | 5 (33) | 1 (7) | 3 (20) | 3 (20) | 3 (20) | 0 |
| Prostate | 13 | 3 (23) | 0 | 2 (15) | 1 (8) | 4 (31) | 3 (23) |
| Lung | 9 | 1 (11) | 2 (22) | 1 (11) | 4 (44) | 1 (11) | 0 |
| Cervix | 7 | 2 (29) | 2 (29) | 1 (14) | 0 | 0 | 2 (29) |
| Other | 41 | 12 (29) | 7 (17) | 8 (20) | 5 (12) | 2 (5) | 7 (17) |
| Primary therapy† | |||||||
| CT only | 121 | 21 (17) | 38 (31) | 25 (21) | 11 (9) | 15 (12) | 11 (9) |
| RT only | 43 | 14 (33) | 6 (14) | 6 (14) | 6 (14) | 5 (12) | 6 (14) |
| CMT | 139 | 26 (19) | 40 (29) | 34 (24) | 14 (10) | 18 (13) | 7 (5) |
Two patients, one each with abnormal chromosome 5 or 7, are counted only in the balanced rearrangement category because of t(3;21) or inv(16). Patients with abnormalities of 5, 7, or both plus other abnormalities except balanced rearrangement are counted only in the abnormal chromosome 5, 7, or both categories.
P < .0001 as measured by Fisher exact test for comparison of the 3 major categories of no malignancy, hematologic malignancy, and solid tumor (3 × 6 contingency table).
P = .19.